Meditope Biosciences, Inc. is in possession of a revolutionary antibody platform technology called “SnAP” (Site-specific, novel, Antibody Platform), which can turn antibodies into a LEGO-like system. The power, elegance, and simplicity of SnAP allows for a broad range of molecules – toxins, proteins, radiolabels, other antibodies – to be ‘snapped’ on or off an antibody with predictability, precision and control. Meditope is using this technology to develop a preclinical pipeline of compelling cancer drugs including two new immuno-oncology product for prostate and bladder cancers.